Daneng Li, MD

Daneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.

Daneng Li, MD, discusses the results of the REFLECT trial of lenvatinib in hepatocellular carcinoma.